Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab induction study in biologic-failed moderate to severe ulcerative colitis
MOH_2018-11-19_002447Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in autoimmune colitis (9 arms), sponsored by AbbVie Inc. Started Apr 2018; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2018-11-19_002447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-19_002447.